Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
14.96
+0.84 (5.95%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Anika Therapeutics Revenue
In the year 2025, Anika Therapeutics had annual revenue of $112.82M, down -5.91%. Anika Therapeutics had revenue of $30.62M in the quarter ending December 31, 2025, with 0.04% growth.
Revenue (ttm)
$112.82M
Revenue Growth
-5.91%
P/S Ratio
1.78
Revenue / Employee
$391,733
Employees
288
Market Cap
200.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 112.82M | -7.09M | -5.91% |
| Dec 31, 2024 | 119.91M | -885.00K | -0.73% |
| Dec 31, 2023 | 120.79M | 6.97M | 6.12% |
| Dec 31, 2022 | 113.83M | -33.97M | -22.98% |
| Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Evolus | 297.18M |
| Aurora Cannabis | 272.13M |
| Akebia Therapeutics | 236.20M |
| Organigram Global | 204.21M |
| Lifecore Biomedical | 128.87M |
| Journey Medical | 59.40M |
| Alpha Teknova | 40.52M |
ANIK News
- 5 days ago - Top 2 Health Care Stocks That May Crash This Quarter - Benzinga
- 11 days ago - Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Anika Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 19 days ago - Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference - GlobeNewsWire
- 25 days ago - Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewsWire
- 6 weeks ago - ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewsWire
- 4 months ago - Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Anika Reports Third Quarter 2025 Financial Results - GlobeNewsWire